摘要
肺癌作为我国主要的癌症死因日益受到关注,目前治疗上主要依赖于化疗、靶向治疗和免疫治疗,但这些方法在临床应用中常出现耐药性、疾病进展等问题,亟需探索更为有效的手段以改善患者的预后。抗体偶联药物(antibody-drug conjugates,ADC)作为一种新兴的抗肿瘤治疗手段,由3个核心部分构成:特异性靶向肿瘤细胞的单克隆抗体、具有高度细胞毒性的药物载荷,以及将二者连接的连接子。ADC通过特异性抗体与肿瘤细胞表面抗原的结合,将细胞毒性载荷定向运送至肿瘤细胞,克服了传统化疗药物和单克隆抗体治疗的局限性。本文综述了ADC在肺癌治疗领域的最新研究进展,探讨了其在疗效和安全性方面的治疗潜力,旨在为临床治疗肺癌提供参考。
Lung cancer is a leading cause of cancer-related mortality in China,commanding increasing attention.The prevailing therapeutic strategies rely on chemotherapy,targeted therapy and immunotherapy.However,the emergence of drug resistance and disease progression are inevitable challenges in clinical practice,underscoring an imperative for the development of more efficacious strategies to enhance patient prognoses.Antibody-drug conjugate(ADC),as an innovative anti-tumor therapy,is composed of three key elements:monoclonal antibodies that specifically target tumor cells,highly cytotoxic drug payload,and linker that connect these two components.By binding the specific antibodies to antigens on the surface of tumor cells,ADC deliver the cytotoxic payload directly to the tumor cells,thus overcoming the limitations of traditional chemotherapy and monoclonal antibody therapies.This article provides a comprehensive review of the latest research advancements of ADC in the field of lung cancer treatment,discussing their therapeutic potential in terms of efficacy and safety,with the aim of offering a reference for the clinical management of lung cancer.
作者
许杨悦
马佩
束永前
XU Yangyue;MA Pei;SHU Yongqian(Department of oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《南京医科大学学报(自然科学版)》
北大核心
2025年第1期98-104,共7页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金(82172889)。
关键词
抗体偶联药物
肺癌
靶向治疗
antibody-drug conjugates
lung cancer
targeted therapy
作者简介
通信作者:束永前,E-mail:yongqian_shu@163.com,ORCID:0000-0002-3034-685X。
